Cargando…
Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
Hereditary angioedema (HAE) is a rare genetic disorder, characterized by recurrent and unexpected potentially life-threatening mucosal swelling. The impairment underlying HAE could be a defect in C1-inhibitor activity, or in its serum concentration. Patients affected by HAE should be treated with on...
Autores principales: | Nicola, Stefania, Rolla, Giovanni, Brussino, Luisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788388/ https://www.ncbi.nlm.nih.gov/pubmed/31645881 http://dx.doi.org/10.7573/dic.212605 |
Ejemplares similares
-
Corrigendum: Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research
Publicado: (2019) -
Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010) -
Improving the Management of Hereditary Angioedema
por: Giavina-Bianchi, Pedro, et al.
Publicado: (2018) -
Pathophysiology and underlying mechanisms in hereditary angioedema
por: Lera, Alberto López
Publicado: (2021) -
Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)